- Home
- CRT vs ACET Comparison
CRT vs ACET Comparison
Compare CRT & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- ACET
- Stock Information
- Founded
- CRT 1991
- ACET 1947
- Country
- CRT United States
- ACET United States
- Employees
- CRT N/A
- ACET N/A
- Industry
- CRT Oil & Gas Production
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- ACET Health Care
- Exchange
- CRT Nasdaq
- ACET Nasdaq
- Market Cap
- CRT 65.1M
- ACET 69.9M
- IPO Year
- CRT 1992
- ACET N/A
- Fundamental
- Price
- CRT $7.70
- ACET $0.81
- Analyst Decision
- CRT
- ACET Buy
- Analyst Count
- CRT 0
- ACET 4
- Target Price
- CRT N/A
- ACET $5.50
- AVG Volume (30 Days)
- CRT 25.2K
- ACET 1.7M
- Earning Date
- CRT 01-01-0001
- ACET 11-05-2025
- Dividend Yield
- CRT 9.63%
- ACET N/A
- EPS Growth
- CRT N/A
- ACET N/A
- EPS
- CRT 0.92
- ACET N/A
- Revenue
- CRT $6,559,820.00
- ACET N/A
- Revenue This Year
- CRT N/A
- ACET N/A
- Revenue Next Year
- CRT N/A
- ACET N/A
- P/E Ratio
- CRT $8.33
- ACET N/A
- Revenue Growth
- CRT N/A
- ACET N/A
- 52 Week Low
- CRT $7.14
- ACET $0.45
- 52 Week High
- CRT $13.31
- ACET $1.54
- Technical
- Relative Strength Index (RSI)
- CRT 42.69
- ACET 49.83
- Support Level
- CRT $7.38
- ACET $0.79
- Resistance Level
- CRT $7.75
- ACET $1.03
- Average True Range (ATR)
- CRT 0.21
- ACET 0.06
- MACD
- CRT 0.06
- ACET 0.00
- Stochastic Oscillator
- CRT 75.24
- ACET 18.11
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.